Ophthalmology · Lake Mary, FL
NPI
1487654117
Since 2005
Specialty
Ophthalmology
Code 207W00000X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
1025 Primera Blvd
Lake Mary, FL, 32746
Phone (407) 333-1570
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.7M
33,729 services
Medicare patients, 2024
1,613
Average age 79
Drug cost, 2024
$510K
1,590 prescriptions
Company payments, 2025
$1,074
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Thomas A Barnard was code J2777 (injection, faricimab-svoa, 0.1 mg), 12,720 times for 39 patients. In total Thomas A Barnard billed 33,729 services in 50 codes, and Medicare paid $4.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-04-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2777 Injection, faricimab-svoa, 0.1 mg | Office | 12,720 | 39 | $27.09 | $345K |
| J0178 Injection, aflibercept, 1 mg | Office | 3,868 | 391 | $644.61 | $2.5M |
| J2781 Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2,895 | 37 | $116.25 | $337K |
| 67028 Intravitreal Injection | Office | 2,461 | 575 | $96.47 | $237K |
| 92134 Computerized Ophthalmic Imaging | Office | 2,387 | 908 | $29.35 | $70K |
| Q5128 Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 1,906 | 87 | $179.13 | $341K |
| 92250 Angiography | Office | 1,312 | 1,143 | $25.86 | $34K |
| J0177 Injection, aflibercept hd, 1 mg | Office | 1,232 | 38 | $259.15 | $319K |
| 92014 Ophthalmological E&M | Office | 1,052 | 898 | $83.70 | $88K |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 793 | 185 | $48.39 | $38K |
| 99213 Office E&M - Established | Office | 782 | 565 | $66.10 | $52K |
| 92012 Ophthalmological E&M | Office | 391 | 355 | $62.91 | $25K |
| 99427 Chronic, Principal, and Transitional Care Management | Office | 342 | 159 | $36.71 | $13K |
| 92004 Ophthalmological E&M | Office | 196 | 196 | $104.65 | $21K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 180 | 29 | $0.68 | $123 |
By year: 2022 $4.1M for 23,317 services; 2023 $4.5M for 34,180 services; 2024 $4.7M for 33,729 services.
Medicare prescription drug claims, 2024
In 2024, the drug Thomas A Barnard prescribed most often to Medicare patients was Prednisolone Acetate, with 339 prescriptions and refills. In total Thomas A Barnard wrote 1,590 Medicare prescriptions that cost $510K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisolone Acetate Generic | 339 | 459 | 163 | $12K |
| Latanoprost Generic | 270 | 504 | 81 | $3,061 |
| Brimonidine Tartrate Generic | 170 | 307 | 61 | $1,208 |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 142 | 147 | 104 | $1,811 |
| Timolol Maleate Generic | 137 | 274 | 43 | $1,573 |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 122 | 243 | 41 | $1,632 |
| Eylea Aflibercept | 109 | 116 | 25 | $272K |
| Vabysmo Faricimab-Svoa | 29 | 29 | Under 11 | $84K |
| Moxifloxacin Moxifloxacin Hcl | 25 | 26 | 13 | $348 |
| Atropine Sulfate Generic | 23 | 40 | 16 | $781 |
| Loteprednol Etabonate Generic | 23 | 29 | Under 11 | $2,936 |
| Dorzolamide Hcl Generic | 20 | 39 | Under 11 | $312 |
| Syfovre Pegcetacoplan/Pf | 18 | 18 | Under 11 | $66K |
| Restasis Cyclosporine | 15 | 21 | Under 11 | $13K |
| Lumigan Bimatoprost | 15 | 17 | Under 11 | $4,326 |
Brand drugs: 675 claims; generic drugs: 915 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Thomas A Barnard $1,074 ($1,074 in general payments such as food, travel and fees) from 6 companies. The largest payer was ANI Pharmaceuticals, Inc. with $283.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.